Close Menu

Small Wins Big

This week, The Scientist ranks readers' picks for the top 40 places to work in industry in 2011. Notably, the top three firms overall are each staffed by no more than 100 employees. This year, Epizyme — the Cambridge, Mass.-based drug-development company, which has fewer than 50 employees — takes top honors. The Scientist notes the firm's "integrity" and "communications" as its greatest strengths.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.